ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Analyst Price Targets - Benzinga

ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc.

ZVSAOTCPK

Trade with Public

Trade with Public

$0.0990

-0.21-68.2%

Last update: Sep 4, 12:22 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare

ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. (ZVSA).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$12Upside to Avg. PT+12021.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 26, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$12
Mar 12, 2024	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$24→$12
Feb 29, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$24
Sep 8, 2023	HC Wainwright & Co.	Ed Arce	Initiate	Buy	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ZyVersa Therapeutics, Lowers Price Target to $12

HC Wainwright & Co. analyst Ed Arce maintains ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and lowers the price target from $24 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $24 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and maintains $24 price target.

Benzinga Newsdesk

Microcap Firm ZyVersa Therapeutics Shows Promise Despite IPO Volatility, Analyst Initiates With Buy

HC Wainwright initiated coverage on ZyVersa Therapeutics Inc (NASDAQ: ZVSA) with a Buy Rating and a

Vandana Singh

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023

Benzinga Insights

PRO
HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics with Buy Rating, Announces Price Target of $2.5

HC Wainwright & Co. analyst Ed Arce initiates coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and announces Price Target of $2.5.

Benzinga Newsdesk